Anginovag spray oromucosal

Država: Armenija

Jezik: angleščina

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktivna sestavina:

dequalinium (dequalinium chloride), tyrothricin, enoxolone, hydrocortisone (hydrocortisone acetate), lidocaine (lidocaine hydrochloride)

Dostopno od:

Ferrer Internacional

Koda artikla:

առկա չէ (R02A)

INN (mednarodno ime):

dequalinium (dequalinium chloride), tyrothricin, enoxolone, hydrocortisone (hydrocortisone acetate), lidocaine (lidocaine hydrochloride)

Odmerek:

1mg/ml+ 4mg/ml+ 0.6mg/ml+ 0.6mg/ml+ 1mg/ml

Farmacevtska oblika:

spray oromucosal

Enote v paketu:

20ml (200 doses) plastic container and pump dispenser

Tip zastaranja:

OTC

Status dovoljenje:

Registered

Datum dovoljenje:

2020-12-30

Lastnosti izdelka

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ANGINOVAG Oromucosal spray solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Composition per 1 ml :
Dequalinium chloride
....................................................................................................................
1,0 mg
Enoxolone
.......................................................................................................................................
0,6 mg
Hydrocortisone acetate
..................................................................................................................
0,6 mg
Tyrothricin
......................................................................................................................................
4,0 mg
Lidocaine hydrochloride
................................................................................................................
1,0 mg
Excipient(s) with known effect :
Propylene glycol and ethanol 96%
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oromucosal spray solution.
Clear, colourless or slightly yellow solution
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Preventive and curative therapy of oropharyngeal affections:
Amygdalitis, pharyngitis, laryngitis, stomatitis, oral ulcers and
aphthae, glossitis.
4.2
Posology and method of administration
Posology
Oropharyngeal use.
Adults and children over 13 years old
Attack dose: 1-2 applications every 2-3 hours.
Maintenance or preventive dose: One application every 6 hours.
Paediatric population
The safety and efficacy of Anginovag in children aged under 13 years
old have not yet been
established.
Method of administration
Open the mouth widely. Point the inhaler mouthpiece to the affected
area (throat, mouth, tongue, etc,
depending on the case).
Push the upper part of the cap from top to bottom up to the limit,
keeping the bottle in upright position.
The bottle is supplied with a metering valve: each actuation up to the
limit causes the regulated drug
delivery.
4.3
Contra